The Determination and Control of Genotoxic Impurities in APIs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Determination and Control of Genotoxic Impurities in APIs
The authors provide an overview of methods for the quantitative determination of genotoxic impurities (GTIs) in active pharmaceutical ingredients.


Pharmaceutical Technology
Volume 35, pp. s24-s30

References

1. ICH, S2 (R1) Guideline on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use (2008).

2. T. McGovern and D.J. Kram, Trends Analyt. Chem. 25 (8), 790–795 (2006).

3. ICH, Q3A (R2) Guideline on Impurities in New Drug Substances (2006).

4. ICH, Q3C(R4) Guideline for Residual Solvents (2009).

5. R. Kroes et al., Food Chem. Toxicol. 42 (1), 65–83 (2004).

6. EMA, Guideline on the Limits of Genotoxic Impurities (London, January 2007).

7. EMA, Guideline on the Limits of Genotoxic Impurities (February 2009).

8. L. Muller et al., Regul. Toxicol. Pharmacol. 44 (3), 198–211 (2006).

9. M. Sun, D.Q. Liu, and A.S. Kord, Org. Process Res. Dev. 14 (4), 977–985 (2010).

10. D.Q. Liu, M. Sun, and A.S. Kord, J. Pharm. Biomed. Anal. 51 (5), 999–1014 (2010).

11. D.Q. Liu et al., J. Pharm. Biomed. Anal. 50 (2), 144–150 (2009).

12. N.V.V.S.S. Raman et al., J. Pharm. Biomed. Anal. 48 (1), 227–230 (2008).

13. D.P. Elder et al., J. Pharm. Sci. 99 (7), 2948–2961 (2010).

14. L. Bai et al., J. Chromatogr. A 1217 (3), 302–306 (2010).

15. E.J. Delaney, Regul. Toxicol. Pharmacol. 49 (2), 107–124 (2007).

16. K. Ramakrishna, J. Pharm. Biomed. Anal. 46 (4), 780–783 (2008).

17. R. Alzaga et al., J. Pharm. Biomed. Anal. 45 (3), 472–479 (2007).

18. N.V.V.S.S. Raman et al., Talanta 77 (5), 1869–1872 (2009).

19. A. Teasdale, Org. Process Res. Dev. 13 (3), 429–433 (2009).

20. F.N. Onyezili, Analyst 114 (1), 789–791 (1989).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here